Pinokalant

Pinokalant is a broad-spectrum and non-selectivecation channel inhibitor. Pinokalant significantly reduces cortical infarct volume. Pinokalant o improves the metabolic and electrophysiologic status of the ischemic penumbra. Pinokalant reduces lesion size on magnetic resonance images in the acute phase following middle cerebral artery occlusion in rats. Pinokalant has the potential for the research of stroke. Pinokalant also shows anti-SARS-CoV-2 activity[1].

Product Specifications

CAS Number

[149759-26-2]

Product Name Alternative

LOE-908

UNSPSC

12352005

Target

SARS-CoV; TRP Channel

Type

Reference compound

Related Pathways

Anti-infection; Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/pinokalant.html

Purity

99.09

Solubility

DMSO : 7.2 mg/mL (ultrasonic; warming)

Smiles

O=C(C(C1=NCCC2=C1C=C(C(OC)=C2)OC)C3=CC=CC=C3)N(CCC4=CC=C(C(OC)=C4OC)OC)CCC5=CC=C(C(OC)=C5OC)OC

Molecular Formula

C41H48N2O9

Molecular Weight

712.83

References & Citations

[1]Christensen T, et al. The broad-spectrum cation channel blocker pinokalant (LOE 908 MS) reduces brain infarct volume in rats: a temperature-controlled histological study. Basic Clin Pharmacol Toxicol. 2005 Apr;96 (4) :316-24. |[2]Simard JM, et al. Non-selective cation channels, transient receptor potential channels and ischemic stroke. Biochim Biophys Acta. 2007 Aug;1772 (8) :947-57.|[3]Serdar Durdagi, et al. Screening of Clinically Approved and Investigation Drugs as Potential Inhibitors of SARS-CoV-2 Main Protease and Spike Receptor-Binding Domain Bound with ACE2 COVID19 Target Proteins: A Virtual Drug Repurposing Study. 2020.